公开(公告)号：EP2029543B1

公开(公告)日：2015-11-18

申请号：EP07796104.3

申请日：2007-06-13

申请人： Wyeth LLC

发明人： COLE, Derek, Cecil ,  BOSCHELLI, Diane, Harris ,  WANG, Yanong, Daniel ,  ASSELIN, Magda ,  JOSEPH-MCARTHY, Diane, Marie ,  PRASHAD, Amarnauth, Shastrie ,  WISSNER, Allan ,  DUSHIN, Russell ,  WU, Biqi ,  TUMEY, Lawrence, Nathan ,  NIU, Chuan, S. ,  CHEN, Joan

IPC分类号： C07D213/85 ,  A61K31/465 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

CPC分类号： C07D213/85 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

公开(公告)号：EP2029543A2

公开(公告)日：2009-03-04

申请号：EP07796104.3

申请日：2007-06-13

申请人： Wyeth

发明人： COLE, Derek, Cecil ,  BOSCHELLI, Diane, Harris ,  WANG, Yanong, Daniel ,  ASSELIN, Magda ,  JOSEPH-MCARTHY, Diane, Marie ,  PRASHAD, Amarnauth, Shastrie ,  WISSNER, Allan ,  DUSHIN, Russell ,  WU, Biqi ,  TUMEY, Lawrence, Nathan ,  NIU, Chuan, S. ,  CHEN, Joan

IPC分类号： C07D213/85 ,  A61K31/465 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

CPC分类号： C07D213/85 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

摘要： The present teachings provide compounds of formula I or a pharmaceutically acceptable salt, hydrate, or ester thereof, wherein: X is selected from a) -NR3-Y-, b) -O-Y-, c) -S(O)m-Y-, d) -S(O)mNR3- Y-, e) -NR3S(O)m-Y-, f) -C(O)NR3-Y-, g) -C(S)NR3-Y-, h) -NR3C(O)- Y-, i) -NR3C(S)-Y-, j) -C(O)O-Y-, k) -OC(O)-Y-, and I) a covalent bond; Y, at each occurrence, independently is selected from a) a divalent C1-10 to alkyl group, b) a divalent C2-10 alkenyl group, c) a divalent C2-10 alkynyl group, d) a divalent C1-10 haloalkyl group, and e) a covalent bond; R1 is selected from a) a C 1-10 alkyl group, b) a C3-14cycloalkyl group, c) a 3-14 membered cycloheteroalkyl group, d) a C8-14 polycyclic aryl group and e) a 5-14 membered heteroaryl group, wherein each group optionally is substituted with 1-4 -Y-R4; R2 is a C6-14 aryl group or a 5-14 membered heteroaryl group, wherein each group optionally is substituted with 1-4 groups independently selected from -Y-R4 Or -O-Y-R4. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.